Oxiconazole

Summary

Oxiconazole (CHEMBL1262) is an approved small-molecule antiinfective agent (ATC G01AF17).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G01AF17 (+1 more)
• Clinical trials: 1
• Chemistry: 429.1 Da · C18H13Cl4N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1262
Name	Oxiconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5353853
ChEBI	CHEBI:7825
ATC	G01AF17, D01AC11
Molecular formula	C18H13Cl4N3O
Molecular weight	429.1
InChIKey	QRJJEGAJXVEBNE-HKOYGPOVSA-N

SMILES: C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl

IUPAC name: (Z)-1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-ylethanimine

ChEBI definition: An oxime O-ether that is the 2,4-dichlorobenzyl ether of the oxime obtained by formal condensation of hydroxylamine with the carbonyl group of acetopnenone in which the phenyl group is substituted by chlorines at positions 2 and 4, and in which one of the hydrogens of the methyl group is replaced by a 1H-imidazol-1-yl group. An antifungal agent, it is used (generally as the nitrate salt) in creams and powders for the topical treatment of fungal skin infections.

Pharmacological roles (ChEBI): antiinfective agent.

Also known as: Oxiconazol, Oxiconazole, Oxizole, oxiconazole, OXICONAZOLE, OXICONAZOLE NITRATE

Parent form; salt/anhydrous children: CHEMBL1200836

Patent coverage: 28 distinct patent families (48 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 39 (81%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 35 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Thromboxane-A synthase, Alpha-2A adrenergic receptor, Androgen receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Substance-K receptor, Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 55 potent at pChembl ≥ 5 of 61 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	7.4	IC50	40	nM	CHEMBL_ACT_7738221
CYP3A4	7.05	IC50	90	nM	CHEMBL_ACT_7738229
AR	6.77	AC50	168.8	nM	CHEMBL_ACT_25203925
ADORA3	6.45	Ki	358.6	nM	CHEMBL_ACT_7738154
SLC6A4	6.37	Ki	425.1	nM	CHEMBL_ACT_7742438
ADRA2C	6.22	Ki	605.1	nM	CHEMBL_ACT_7738168
TBXAS1	6.21	IC50	617.4	nM	CHEMBL_ACT_7742451
ADORA3	6.2	IC50	634.5	nM	CHEMBL_ACT_7738153
DRD3	6.17	Ki	677.1	nM	CHEMBL_ACT_7738236
SLC6A4	6.1	IC50	800.1	nM	CHEMBL_ACT_7742437
ADORA3	6.05	AC50	892	nM	CHEMBL_ACT_25199173
CHRM3	6.02	Ki	960.4	nM	CHEMBL_ACT_7740332
CYP2D6	6	IC50	1000	nM	CHEMBL_ACT_7738225
TACR2	5.97	Ki	1074	nM	CHEMBL_ACT_7742448
CHRM1	5.94	Ki	1141	nM	CHEMBL_ACT_7740328
HTR2A	5.92	Ki	1189	nM	CHEMBL_ACT_7742426
ADRA2A	5.82	Ki	1531	nM	CHEMBL_ACT_7738164
ADRA2B	5.78	Ki	1666	nM	CHEMBL_ACT_7738166
OPRD1	5.73	Ki	1871	nM	CHEMBL_ACT_7740348
SLC6A2	5.72	IC50	1910	nM	CHEMBL_ACT_7738175
SLC6A2	5.72	Ki	1894	nM	CHEMBL_ACT_7738176
DRD3	5.7	IC50	1994	nM	CHEMBL_ACT_7738235
DRD1	5.68	Ki	2068	nM	CHEMBL_ACT_7738232
SLC6A3	5.68	Ki	2110	nM	CHEMBL_ACT_7740274
SLC6A2	5.63	AC50	2339	nM	CHEMBL_ACT_25146567
SLC6A3	5.58	AC50	2616	nM	CHEMBL_ACT_25125526
SLC6A3	5.58	IC50	2656	nM	CHEMBL_ACT_7740273
SLC6A4	5.57	AC50	2716	nM	CHEMBL_ACT_25151894
PGR	5.53	AC50	2934	nM	CHEMBL_ACT_25204858
HTR2B	5.53	Ki	2931	nM	CHEMBL_ACT_7742428
CYP2C9	5.52	IC50	3000	nM	CHEMBL_ACT_7738223
OPRM1	5.51	AC50	3094	nM	CHEMBL_ACT_25158742
P19327	5.5	Ki	3187	nM	CHEMBL_ACT_7740406
TACR2	5.49	IC50	3222	nM	CHEMBL_ACT_7742447
ADRB3	5.45	Ki	3559	nM	CHEMBL_ACT_7738174
ADRA2B	5.44	IC50	3650	nM	CHEMBL_ACT_7738165
ADRA2A	5.39	IC50	4083	nM	CHEMBL_ACT_7738163
KCNH2	5.38	AC50	4200	nM	CHEMBL_ACT_25118771
ADRA2C	5.38	IC50	4164	nM	CHEMBL_ACT_7738167
DRD1	5.38	IC50	4136	nM	CHEMBL_ACT_7738231
HTR2A	5.38	IC50	4163	nM	CHEMBL_ACT_7742425
DRD3	5.36	AC50	4391	nM	CHEMBL_ACT_25195073
PTGS1	5.35	AC50	4430	nM	CHEMBL_ACT_25206721
CHRM3	5.34	IC50	4531	nM	CHEMBL_ACT_7740331
HTR2B	5.34	IC50	4606	nM	CHEMBL_ACT_7742427
ACHE	5.33	IC50	4646	nM	CHEMBL_ACT_7738147
CHRM1	5.33	IC50	4736	nM	CHEMBL_ACT_7740327
ADRB3	5.32	IC50	4745	nM	CHEMBL_ACT_7738173
OPRD1	5.28	IC50	5308	nM	CHEMBL_ACT_7740347
P19327	5.25	IC50	5577	nM	CHEMBL_ACT_7740405
DRD1	5.18	AC50	6562	nM	CHEMBL_ACT_25115777
TBXA2R	5.18	AC50	6652	nM	CHEMBL_ACT_25198410
ADRA1A	5.16	AC50	6904	nM	CHEMBL_ACT_25219340
CHRM1	5.12	AC50	7559	nM	CHEMBL_ACT_25210703
ADRA2A	5.11	AC50	7826	nM	CHEMBL_ACT_25156996

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07441005	EARLY_PHASE1	COMPLETED	Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).